Peripheral Blood iPS Cell Reprogramming with Lipid Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing induced pluripotent stem cells (iPS cells) using viral vectors face risks of vector persistence and viral contamination, while lipofection methods struggle with stability and homogeneity.
Innovation Solution
An initialization agent comprising lipid nanoparticles encapsulating initialization factors, primarily FFT-10 and FFT-20, is used to reprogram mononuclear cells from peripheral blood into iPS cells, ensuring stability and homogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used to express initialization factors, then iPS cells can be produced, but there is a risk that the vector will remain in the infected cell and continue to express initialization factors, and there is a risk that the virus may remain in the final product
Solution Approach 1:
The patent extracts the harmful viral vector component and replaces it with a non-viral lipid nanoparticle delivery system. The initialization factors are delivered via lipofection using lipid nanoparticles, which eliminates the risk of viral persistence and contamination while maintaining the ability to express initialization factors and produce iPS cells
Solution Approach 2:
The patent introduces lipid nanoparticles as an intermediary carrier to deliver initialization factors to cells. This intermediary system replaces the viral vector, allowing transient expression of initialization factors without the harmful effects of viral persistence, thereby ensuring high purity of the final iPS cell product
2Reliability
If lipofection is used to express initialization factors, then viral risks are eliminated, but it is not easy to stably or homogeneously produce iPS cells
Solution Approach 1:
The patent optimizes parameters of the lipid nanoparticle system, including the ratio of ionizable lipid to helper lipid, charge density, and particle size, to achieve stable and homogeneous delivery of initialization factors. These parameter optimizations ensure consistent reprogramming efficiency and homogeneous production of iPS cells while maintaining viral-free purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves efficient and stable production of iPS cells by encapsulating initialization factors in lipid nanoparticles, minimizing viral risks and improving production consistency.
Implementation Method 1
there is also a method that uses lipofection, but it is not easy to stably or homogeneously produce iPS cells when using this method
Data Source
AI summary
According to one embodiment, an initialization agent is for initializing blood cells derived from peripheral blood. The initialization agent includes an initialization factor group for producing iPS cells by initializing a group of blood cells including mononuclear cells derived from peripheral blood, and a group of lipid nanoparticles that encapsulate the initialization factor group. The lipid nanoparticles have a component of at least or more of 40% FFT-10 and FFT-20. FFT-10 and FFT-20 are included in equal amounts.